GlassScriptPhysician profile
Raiyan Islam
NPI 1649809302
$2,344.05
in general payments reported to CMS, 2019-2025
30 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $141 · 2024: $449 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623 · Education: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.40 |
| Education | $579.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $350.46 | 2024-2025 | Jakafi, Niktimvo |
| Astellas Pharma US INC | $216.71 | 2025 | Vyloy |
| Seagen INC. | $192.98 | 2025 | |
| Pfizer INC. | $169.26 | 2025 | |
| Janssen Biotech, INC. | $151.19 | 2024-2025 | Rybrevant, Erleada |
| Merck Sharp & Dohme LLC | $119.96 | 2024-2025 | Keytruda, Reblozyl, Lynparza |
| Alexion Pharmaceuticals, INC. | $113.36 | 2024-2025 | Ultomiris |
| Abbvie INC. | $102.41 | 2025 | |
| Genentech USA, INC. | $92.26 | 2025 | Tecentriq Hybreza, Phesgo, Venclexta |
| Horizon Therapeutics Plc | $89.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.70 | 2024-2025 | Ninlaro, Alunbrig |
| Sobi, INC | $69.96 | 2024-2025 | |
| Array Biopharma INC | $69.03 | 2025 | Braftovi, Mektovi, Tukysa |
| Regeneron Healthcare Solutions, INC. | $58.86 | 2024-2025 | Libtayo |
| Daiichi Sankyo INC. | $53.40 | 2025 | Datroway, Enhertu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $49.81 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $49.67 | 2025 | |
| Glaxosmithkline, LLC. | $42.47 | 2025 | Zejula, Jemperli, Blenrep |
| Genzyme Corporation | $40.64 | 2025 | |
| Puma Biotechnology, INC. | $37.91 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $23.94 | 2025 | Provenge |
| Recordati_rare_diseases_inc. | $21.02 | 2024 | Sylvant |
| E.R. Squibb & Sons, L.L.C. | $20.90 | 2025 | Reblozyl |
| Lilly USA, LLC | $18.60 | 2025 | Jaypirca, Verzenio |
| Jazz Pharmaceuticals INC. | $18.31 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.05 | 2025 | |
| Apellis Pharmaceuticals, INC. | $17.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.44 | 2024 | Xarelto |
| Morphosys, US INC. | $17.07 | 2022 | |
| Amgen INC. | $16.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raiyan Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.